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Summary
Mycoplasma hyopneumoniae (M. hyopneumoniae) is the primary pathogen of enzootic
pneumonia, a chronic respiratory disease in pigs. Infections occur worldwide and
cause major economic losses to the pig industry. The present paper reviews the cur-
rent knowledge on M. hyopneumoniae infections, with emphasis on identification
and analysis of knowledge gaps for optimizing control of the disease. Close contact
between infected and susceptible pigs is the main route of M. hyopneumoniae trans-
mission. Management and housing conditions predisposing for infection or disease
are known, but further research is needed to better understand M. hyopneumoniae
transmission patterns in modern pig production systems, and to assess the impor-
tance of the breeding population for downstream disease control. The organism is
primarily found on the mucosal surface of the trachea, bronchi and bronchioles. Dif-
ferent adhesins and lipoproteins are involved in the adherence process. However, a
clear picture of the virulence and pathogenicity of M. hyopneumoniae is still missing.
The role of glycerol metabolism, myoinositol metabolism and the Mycoplasma Ig
binding protein—Mycoplasma Ig protease system should be further investigated for
their contribution to virulence. The destruction of the mucociliary apparatus,
together with modulating the immune response, enhances the susceptibility of
infected pigs to secondary pathogens. Clinical signs and severity of lesions depend
on different factors, such as management, environmental conditions and likely also
M. hyopneumoniae strain. The potential impact of strain variability on disease sever-
ity is not well defined. Diagnostics could be improved by developing tests that may
detect virulent strains, by improving sampling in live animals and by designing ELI-
SAs allowing discrimination between infected and vaccinated pigs. The currently
available vaccines are often cost-efficient, but the ongoing research on developing
new vaccines that confer protective immunity and reduce transmission should be
continued, as well as optimization of protocols to eliminate M. hyopneumoniae from
pig herds.
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1 | INTRODUCTION
Mycoplasma hyopneumoniae (M. hyopneumoniae) is the primary
pathogen of enzootic pneumonia (EP), a chronic respiratory disease
in pigs, and one of the primary agents involved in the porcine respi-
ratory disease complex (PRDC; Thacker & Minion, 2012). Infections
with M. hyopneumoniae are highly prevalent worldwide and cause
tremendous financial losses to the pig industry. Losses are mainly
due to costs for treatment and vaccination, decreased performance
and increased mortality derived from secondary infections (Holst,
Yeske, & Pieters, 2015).
Similar to other Mycoplasmas, M. hyopneumoniae has a small
genome, lacks a cell wall and is pleomorphic. M. hyopneumoniae is
very difficult to isolate because of its slow growth and potential
overgrowth with other swine mycoplasmas. Bacterial culture is usu-
ally attempted when an isolate is deemed, but not for routine diag-
nostics. The organism is primarily identified on the mucosal surface
of the trachea, bronchi and bronchioles (Blanchard et al., 1992). It
affects the mucosal clearance system by disrupting the cilia on the
epithelial surface, and additionally, the organism modulates the
immune system of the respiratory tract (Thacker & Minion, 2012).
Therefore, M. hyopneumoniae predisposes animals to concurrent
infections with other respiratory pathogens including bacteria, para-
sites and viruses. Infections also lead to increased use of antimicro-
bials. While M. hyopneumoniae can be virtually recovered from pigs
of all sites in segregated production systems, the clinical presenta-
tion of EP is mainly observed in growing and finishing pigs. Vaccina-
tion against M. hyopneumoniae is widely practiced and is often cost-
efficient in affected herds. Additional control measures include opti-
mizing management and biosecurity, reducing other risk factors and
disease elimination.
The present paper reviews the current knowledge on M. hyop-
neumoniae infections, with emphasis on identification and analysis of
knowledge gaps for optimizing control measures.
2 | EPIDEMIOLOGY
To date, domestic pigs and wild boar are the only hosts known to
become infected with M. hyopneumoniae. In pigs, there is no clear
indication of susceptibility based on age, although clinical presenta-
tion of the disease is usually evident in grow-finishing stages. Close
contact between infected and susceptible pigs is the main route of
M. hyopneumoniae transmission. Piglets are considered free from
M. hyopneumoniae at birth, as in utero transmission has not been
documented, and first exposure events occur during the lactation
period, when piglets are in contact with dams shedding the microor-
ganism (Calsamiglia & Pijoan, 2000; Nathues et al., 2013a,b). In fact,
the length of the lactation period has been suggested as one risk
factor for piglet colonization with M. hyopneumoniae prior to wean-
ing (Pieters et al., 2014).
Piglet colonization with M. hyopneumoniae at weaning age is of
special importance in segregated production systems, where pigs are
transferred to clean facilities for the growing and finishing phases. It
has been proposed that the initial group colonization with M. hyop-
neumoniae determines downstream clinical presentation and disease
severity (Fano, Pijoan, Dee, & Deen, 2007; Sibila et al., 2007),
although the effect of other factors needs to be considered for dis-
ease presentation as well. The influence of the lactation period dura-
tion in piglet colonization is evidenced by the successful application
of segregated early weaning (SEW) to obtain M. hyopneumoniae-free
pigs born to positive dams (Alexander, Thornton, Boon, Lysons, &
Gush, 1980). Research data have shown that transmission of M. hy-
opneumoniae among pen-mates is slow (Meyns et al., 2004; Roos,
Fano, Homwong, Payne, & Pieters, 2016; Villarreal et al., 2011b), fit-
ting the picture that disease presentation can be the result of early
group colonization and subsequent transmission events. However, a
clear understanding of M. hyopneumoniae transmission in the field is
still needed to improve infection models used in experimental
research.
Dams and piglets in the breeding herds are considered the reser-
voir of M. hyopneumoniae infections for the entire production sys-
tem. Circulation of M. hyopneumoniae is thought to occur among
existing sows and be transmitted to incoming gilts, which are capable
of maintaining the pathogen within the farm and are responsible for
the majority of bacterial shedding to newborn pigs (Calsamiglia &
Pijoan, 2000; Fano, Pijoan, & Dee, 2005). In this manner, the con-
stant addition of gilts and birth of piglets provide critical susceptible
populations needed to maintain pathogen transmission. On the other
hand, infection with M. hyopneumoniae has a long duration, reaching
up to 240 days (Pieters, Pijoan, Fano, & Dee, 2009), complicating
the already slow disease transmission scenario observed in sow
herds. A critical aspect of the epidemiology of M. hyopneumoniae is
based on the long pathogen persistence, which determining factors
are poorly understood. Nevertheless, management practices at the
sow farm such as minimizing cross-fostering and limiting the length
of the lactation period may help mitigating the effect of M. hyopneu-
moniae transmission by decreasing risk factors for piglet colonization
(Nathues et al., 2013a,b; Pieters et al., 2014; Vangroenweghe, Labar-
que, Piepers, Strutzberg-Minder, & Maes, 2015). Therefore, identifi-
cation of risk factors for disease transmission at the sow farm is key
for downstream disease control. In continuous-flow production sys-
tems, M. hyopneumoniae colonization in piglets at weaning may not
be as influential as in segregated systems. In continuous-flow sys-
tems, there is a fairly constant contact between animals of different
ages, facilitating transmission of M. hyopneumoniae. In this respect,
the colonization of piglets at weaning is not the only determining
factor for downstream infection.
An additional source of variability regarding epidemiology of
M. hyopneumoniae lies on the demonstration of distinct strains circu-
lating in the field. Partial sequencing of the P146 gene (Mayor, Zeeh,
Frey, & Kuhnert, 2007) and multiple-locus variable number tandem
repeat analysis (MLVA; Vranckx et al., 2011; Dos Santos et al.,
2015) are commonly used to discriminate M. hyopneumoniae. The
use of M. hyopneumoniae molecular characterization has aided out-
break and area spread investigations, by tracking specific strains. In
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addition, it has enabled research directed at understanding pathogen
variability and its relationship with disease presentation (Michiels
et al., 2017). However, current tools for M. hyopneumoniae charac-
terization are based on the sole evaluation of similarities in specific
loci and do not indicate strain virulence and/or antigenicity. Devel-
opment of molecular characterization methods allowing strain viru-
lence evaluation would be beneficial to tailor control strategies at
the farm level and could shed light on understanding potential cross-
protection among strains.
Vectors do not seem to play an important role in the transmis-
sion of M. hyopneumoniae in pigs; however, little research has been
performed on this topic. Data from Nathues et al. (2012) showed
that personnel working with pigs for several hours could harbour the
bacterium in their upper respiratory tract, as detected via PCR in
nasal swabs; however, the potential for pathogen transmission was
not evaluated. Airborne transmission of M. hyopneumoniae has been
suspected for decades (Goodwin, 1985). Cardona, Pijoan, and Dee
(2005) demonstrated that the microorganism could travel for at least
300 m, and Otake, Dee, Corzo, Oliveira, and Deen (2010) showed
that air samples recovered M. hyopneumoniae DNA from as far as
9.2 km from an infected farm. In the latter case, the air sample was
shown to be infectious when inoculated to animals using a swine
bioassay.
The geographical distribution of M. hyopneumoniae infections is
assumed to be worldwide. The prevalence is low in some Scandina-
vian countries, and Switzerland is free after the application of a
national eradication programme (St€ark et al., 2007). Specific data on
M. hyopneumoniae prevalence by country are not available in the lit-
erature, as the disease is not considered of obligatory report and
does not limit commercial trade.
Wild boar has been shown to harbour M. hyopneumoniae and
may carry identical genotypes found in EP outbreaks (Kuhnert &
Overesch, 2014; Sibila et al., 2010). However, this might be rather
the result of spillover from domestic pig outbreaks than representing
wild boars as a reservoir.
3 | INCUBATION PERIOD AND KINETIC
PATTERN
Under experimental conditions, where usually seronegative animals
are challenged with a high infectious dose of M. hyopneumoniae, lung
lesions and onset of coughing can appear as early as 7–14 days
post-infection (dpi; Blanchard et al., 1992; Lorenzo, Quesada,
Assuncao, Castro, & Rodrıguez, 2006), with maximum severity and
extension of lung lesions occurring around 28 dpi (Villarreal et al.,
2011a). The minimal infectious dose to induce lung lesions was
established at 105 colour-changing units per ml (CCU/ml) per pig
(corresponding to 108 mycoplasmas; Marois, Dory, Fablet, Madec, &
Kobisch, 2010). As differences in virulence among strains do exist,
this minimal infectious dose is probably strain dependent.
Under natural conditions, the incubation period is difficult to pre-
dict as it depends on production system, presence of secondary
infections, immune status of animals, virulence of the M. hyopneumo-
niae strain and infectious pressure (Sibila et al., 2009). Indeed, it was
postulated that a critical mass of pigs should be infected to elicit the
appearance of clinical signs (Calsamiglia, Pijoan, & Trigo, 1999). Nev-
ertheless, in clinically affected farms, seroconversion as well as
coughing would appear after, approximately, 1–6 weeks post-infec-
tion (Leon, Madec, Taylor, & Kobisch, 2001).
Mycoplasma hyopneumoniae is excreted from the respiratory
tract of infected individuals through exhalation of microscopic dro-
plets during coughing episodes and/or by nose-to-nose direct con-
tact (Hermann, Brockmeier, Yoon, & Zimmerman, 2008).
M. hyopneumoniae DNA has also been detected in different samples
from the oral cavity such as oropharyngeal swabs (Fablet, Marois,
Kobisch, Madec, & Rose, 2010; Hermann et al., 2008), oral fluids
(Roos et al., 2016) and tonsillar samples (Fablet et al., 2010; Sibila
et al., 2007).
It is known that sows of different parity number may shed the
organism, the younger ones being the main shedders (Boonsoongn-
ern, Jirawattanapong, & Lertwatcharasarakul, 2012; Sibila et al.,
2007). Practices directed at segregation of parity, giving special
care to parity-one dams and piglets and separating them from the
rest of the herd, have been reported to provide significant control
of M. hyopneumoniae infections in young parity dams (Moore,
2003). Nonetheless, it remains unclear whether this excretion is
uniform and continuous or, on the contrary, is of variable intensity
and intermittent. An experimental longitudinal study showed the
onset of excretion at 7–14 dpi, followed by an irregular and incon-
sistent shedding (detection of M. hyopneumoniae DNA at nasal cav-
ities) up to 91 dpi (Fano et al., 2005). Indeed, longer excretion was
indirectly demonstrated by the transmissibility of M. hyopneumoniae
to na€ıve contact pigs at 214 dpi (Pieters et al., 2009). Under natu-
ral conditions, shedding duration and kinetics are more difficult to
be ascertained, as a low bacterial load is usually present at upper
respiratory tract sites (Hermann et al., 2008; Sibila et al., 2009). In
a study where M. hyopneumoniae detection was assessed in nasal
swabs at nine sampling points through the productive life of pigs,
two of 33 (6%) non-vaccinated animals were continuously nested
PCR positive in the last five sampling points (from 12 to 25 weeks
of age; Sibila et al., 2007). On the contrary, in a longitudinal study
in sows, only 2.4% of them had at least one of the three assessed
respiratory sites (nasal, tonsillar and oropharyngeal swabs) positive
by PCR. For all these positive sows, M. hyopneumoniae was
detected at one of eight sampling occasions (Fablet et al., 2011).
Takeuti, De Barcellos, de Lara, Kunrath, and Pieters (2017) fol-
lowed 44 gilts longitudinally from their weaning until after the
weaning of their first offspring, collecting laryngeal swabs every
30 days in an endemically infected farm, and identified approxi-
mately 20% of gilts negative throughout the study, while other
gilts were positive for M. hyopneumoniae by real-time mostly once,
with a proportion of gilts being positive at multiple samplings.
Therefore, considering that the sow population is the origin of
M. hyopneumoniae circulation, shedding pattern in such population
deserves further investigations.
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4 | PATHOGENICITY
4.1 | Adhesins and lipoproteins
Adhesion along the entire length of cilia of ciliated epithelium of the
respiratory tract (trachea, bronchi and bronchioles) of pigs is the first
step of infection with M. hyopneumoniae followed by induction of
ciliostasis and loss of cilia (Debey & Ross, 1994). The primary adhe-
sin of M. hyopneumoniae is the P97 and its paralogues (Hsu & Min-
ion, 1998). The other family of adhesins, related with P97, is formed
by P102 and its paralogues (Adams, Pitzer, & Minion, 2005). Finally,
P159 is an adhesin unrelated to the other two (Burnett et al., 2006).
Adhesin receptors on the eukaryotic cell are mainly glycosaminogly-
cans and fibronectin. Most of the proteins from the P97/P102 par-
alogue families and P159 are post-translationally processed and
cleaved, a system observed with many other surface-associated pro-
teins (Seymour et al., 2010). Like that, Tacchi et al. (2016) identified
35 proteins that are endoproteolytically cleaved in M. hyopneumo-
niae. These include not only adhesins but also lipoproteins and even
multifunctional cytosolic proteins “moonlighting” at the cell surface.
This massive processing and cleavage leads to a very dynamic sur-
face topography of M. hyopneumoniae that could well be involved in
host evasion and modulation of the immune response. The cleaved
fragments of the P97/P102 paralogue families and P159 remain on
the cell surface and function as receptors of heparin, plasminogen
and fibronectin, thereby influencing interaction of M. hyopneumoniae
with its host (Bogema et al., 2012; Simionatto, Marchioro, Maes, &
Dellagostin, 2013).
P146 (LppS) is an adhesion lipoprotein containing a serine-rich
region, the genetic basis of it is also used for genotyping (Mayor
et al., 2007). The homolog in Mycoplasma conjunctivae was hypothe-
sized to be involved in pathogenesis, and in M. hyopneumoniae, it is
also proteolytically processed (Belloy, Vilei, Giacometti, & Frey,
2003; Bogema et al., 2012). This together with the fact that M. hy-
opneumoniae can alter the number of consecutive serine repeats in
P146 (so far observed from 9 up to 48) could indicate that it is also
involved in antigen variation and immune evasion (Dos Santos et al.,
2015).
Cell-surface lipoproteins, alternatively called lipid-associated
membrane proteins (LAMP), have also been found to be implicated
in apoptosis. Whole membrane lipoprotein fractions were shown to
induce apoptosis via caspases 3 and 8 activation in vitro in various
cell types, including porcine peripheral blood mononuclear cells
(PBMC; Bai et al., 2015; Ni et al., 2015). Furthermore, LAMPs acti-
vate production of nitric oxide (NO) and reactive oxygen species
(ROS) in the host cell.
4.2 | H2O2 production
Mycoplasmas in general lack classical virulence factors like toxins. It
has remained obscure for a long time how these smallest self-repli-
cating organisms could elicit toxic effects. Recently, the production
of toxic metabolites like H2O2 was found as a virulence mechanism
of certain mycoplasma species. The bovine pathogen Mycoplasma
mycoides subsp. mycoides SC is able to take up glycerol efficiently,
which is then metabolized by glycerolphosphate oxidase (GlpO) lead-
ing to the production of hydrogen peroxide. Similar metabolic path-
ways account for virulence in the human pathogen Mycoplasma
pneumoniae (Hames, Halbedel, Hoppert, Frey, & Stulke, 2009). For
M. hyopneumoniae, Ferrarini et al. (2016) reconstructed a metabolic
model based on its genome. They postulated an ability of M. hyop-
neumoniae to use glycerol as a carbon source, thereby enabling the
production of hydrogen peroxide. In fact, the homologous gene glpD
is present in M. hyopneumoniae. However, functional assays for test-
ing production of hydrogen peroxide were so far all negative for var-
ious strains of M. hyopneumoniae (Kuhnert, personal communication).
Thus, whether production of toxic metabolic compounds from glyc-
erol is a possible virulence mechanism in M. hyopneumoniae remains
to be investigated.
4.3 | Comparative studies with other Mycoplasmas
Differences in strain virulence have been observed for M. hyopneu-
moniae (Vicca et al., 2003; Villarreal et al., 2009; Woolley et al.,
2012;). Moreover, the most closely related Mycoplasma flocculare is a
commensal of the pig not causing any disease (Siqueira et al., 2013).
This allows for large-scale comparisons on the genome, transcrip-
tome, proteome, metabolome and secretome level in order to find
differences related to virulence and pathogenesis (Ferrarini et al.,
2016; Liu et al., 2013; Paes et al., 2017; Pinto, Klein, Zaha, & Fer-
reira, 2009; Siqueira et al., 2013, 2014). In a study comparing the
pathogenic strain 168 with its attenuated derivative, Liu et al. (2013)
found that besides the known virulence-associated proteins (mainly
adhesins), also mutations in genes involved in metabolism and
growth contribute to virulence. In a genome-reduced organism like
M. hyopneumoniae that lost most of its biosynthetic capacity, it is
not surprising that further loss of gene functions has a dramatic
influence on survival and growth of the microorganism. This also
holds true for, for example, lipoproteins involved in nutrient acquisi-
tion (Browning, Marenda, Noormohammadi, & Markham, 2011). Nev-
ertheless, such attenuated strains could be a basis for live vaccines.
A genome comparison of M. hyopneumoniae and M. flocculare
revealed differences in genome structure and organization (Siqueira
et al., 2013). Some genes of the P97 adhesin family were absent in
M. flocculare, showed sequence differences or were missing domains
involved in adhesion to host cells. However, there were no specific
factors identified that could explain the pathogenic nature of M. hy-
opneumoniae compared to the commensal M. flocculare.
An integrative conjugal element (ICE) has been identified in the
genomes of pathogenic strains 7448 and 232, while it is absent in
the non-pathogenic strain J (Pinto, de Carvalho, Alves-Junior, Broc-
chi, & Schrank, 2007). The ICE from M. hyopneumoniae, called ICEH,
was also found in the pathogenic strain 168 but likewise in its atten-
uated variant (Liu et al., 2013). While ICE, acting as self-replicating
mobile genetic elements, is generally recognized to be involved in
virulence, their role in the pathogenicity of M. hyopneumoniae
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remains unclear. The fact that there are notable differences of ICEH
between the strains indicates that they are at least involved in hori-
zontal gene transfer, thereby maintaining genome plasticity and vari-
ability of M. hyopneumoniae.
Ferrarini et al. (2016) used a genome-scale metabolic modelling
approach to get insight into the virulence of M. hyopneumoniae.
Besides a glycerol conversion pathway potentially leading to perox-
ide production in M. hyopneumoniae, another significant metabolic
pathway was identified to be absent in M. flocculare which is the
myoinositol uptake and catabolism. Functional and in vivo assays
have to be conducted to proof whether these in silico findings play
a role in virulence and pathogenicity.
Differences in virulence could also be due to variation in expres-
sion levels of virulence-associated genes like adhesins. This was
observed in a proteome analysis of in vitro cultures comparing the
non-pathogenic strain J to virulent strains 7448 and 7422 (Pinto
et al., 2009). They identified 64 proteins being overexpressed in the
pathogenic strains compared to the non-pathogenic strain, the most
prominent being P97.
Finally, the secretomes of M. hyopneumoniae and M. flocculare
grown in a serum-reduced medium were compared recently, looking
more precisely at factors directly involved in mycoplasma–host inter-
action (Paes et al., 2017). A higher number of secreted proteins were
found with M. hyopneumoniae compared to M. flocculare (62 versus
26). While M. hyopneumoniae secreted adhesins, methylases, nucle-
ases and lipoproteins, M. flocculare secreted only two adhesins that
were also found in the M. hyopneumoniae secretome. There was a
difference between the transcriptome and the secretome using the
same mycoplasma strains (Siqueira et al., 2014).
These comparative “omics” studies confirmed that adhesins play
a major role in virulence and pathogenesis. However, there are no
clear-cut factors that differ between pathogenic and non-pathogenic
strains or differ between the pathogen M. hyopneumoniae and the
commensal M. flocculare.
4.4 | Mycoplasma–host interaction and immune
modulation
Infection with M. hyopneumoniae is often chronic what indicates a
certain degree of immune evasion of the microbe. In a study looking
at introgression of domestic swine genes into the wild boar popula-
tion, an increased M. hyopneumoniae disease susceptibility in hybrid
animals was observed (Goedbloed et al., 2015). The authors hypoth-
esized that the large-scale use of antibiotics in the swine breeding
sector may have led to selecting deleterious properties of domestic
swine immune genes. These in turn lead to the increased disease
susceptibility if introgression to the wild boar occurs. These observa-
tions confirm a certain host predisposition for M. hyopneumoniae
which in the opposite direction can also be achieved by selecting for
more resistant breeds (Borjigin et al., 2016). Furthermore, it indicates
certain “immune degeneration” of domestic pigs, allowing M. hyop-
neumoniae to cause disease in a well-protected animal. The destruc-
tion of the mucociliary apparatus together with down-modulating
the immune response at later stages enhances the susceptibility of
M. hyopneumoniae-infected pigs to secondary pathogens (Shen, Hu,
Wei, Feng, & Yang, 2017).
The host immune response is considered to be the main driver
of pulmonary lesions. At the same time, M. hyopneumoniae modu-
lates the immune response to persist in the host. Pro-inflammatory
cytokines such as IL-1, TNF-a and IL-6 are induced during infection,
and plasmin is recognized as central to the regulation of inflamma-
tory responses (Woolley, Fell, Djordjevic, Eamens, & Jenkins, 2013).
A number of the P97/P102 adhesin family members interact with
plasminogen of the porcine host and enhance its activation to plas-
min, a serine protease which in turn stimulates macrophage signalling
resulting in production of ROS and cytokine release, thereby con-
tributing to inflammation (Syrovets, Lunov, & Simmet, 2012). A leu-
cine aminopeptidase has recently been shown to “moonlight” as a
multifunctional adhesin, including binding and cleaving of plasmino-
gen, on the M. hyopneumoniae cell surface (Jarocki et al., 2015). Plas-
minogen is readily available in the ciliated airways affected by
M. hyopneumoniae (Seymour et al., 2012).
Interaction with surface accessible actin on the epithelial cells
and causing cytoskeletal rearrangements allows the organism being
phagocytosed. It is hypothesized that M. hyopneumoniae can survive
within the phagolysosome, escape it and reside within the cytoplasm
(Tacchi et al., 2016). Therefore, it can not only evade the immune
system but could disseminate to internal organs and persist within
its host without causing disease. Isolation of M. hyopneumoniae from
other tissue than lung has in fact been reported (Le Carrou, Lauren-
tie, Kobisch, & Gautier-Bouchardon, 2006; Marchioro et al., 2013;
Marois, Le Carrou, Kobisch, & Gautier-Bouchardon, 2007).
Immune evasion by specifically cleaving immunoglobulins has
been described for M. mycoides subsp. capri (Arfi et al., 2016). This
two-protein system consists of a Mycoplasma Ig binding protein
(MIB) and a Mycoplasma Ig protease (MIP), where the MIB is neces-
sary for the proteolytic activity of MIP. The two proteins are
encoded by two genes organized in tandem and often found in mul-
tiple copies in various mycoplasmas including M. hyopneumoniae (Arfi
et al., 2016). How far this MIB-MIP system plays a role in virulence
and immune evasion of M. hyopneumoniae deserves further studies.
A clear picture of virulence and pathogenicity of M. hyopneumo-
niae is still not available The role of glycerol metabolism, myoinositol
metabolism and the MIB-MIP system should be further investigated
for their contribution to virulence.
4.5 | Interaction of M. hyopneumoniae with other
pathogens
Different interactions have been described between M. hyopneumo-
niae and other pathogens. M. hyopneumoniae predisposes pigs to
infections with secondary bacteria. Combined experimental infec-
tions with M. hyopneumoniae and either Pasteurella multocida (P. mul-
tocida) (Amass et al., 1994) or Actinobacillus pleuropneumoniae
(A. pleuropneumoniae) (Marois et al., 2009) result in more severe
lesions compared to the single infections. Co- or subsequent
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infections with P. multocida and A. pleuropneumoniae, and with other
bacteria such as Bordetella bronchiseptica, Haemophilus parasuis, True-
perella pyogenes, streptococci or staphylococci are commonly found
in field outbreaks of EP.
Initial studies focussing on the interaction between M. hyopneu-
moniae and porcine reproductive and respiratory syndrome virus
(PRRSV) could not demonstrate a potentiating effect of both patho-
gens (Van Alstine, Stevenson, & Kanitz, 1996). Subsequently, it was
shown that M. hyopneumoniae significantly prolonged and increased
the severity of PRRSV-induced pneumonia under experimental con-
ditions (Thacker, Halbur, Ross, Thanawongnuwech, & Thacker, 1999).
Dual infection studies with M. hyopneumoniae and swine influenza
virus (SIV) could not show the potentiating effects of both patho-
gens as observed with PRRSV. The effect was less pronounced and
only transitory (Thacker & Thacker, 2001; Yazawa et al., 2004).
Deblanc et al. (2012) showed that M. hyopneumoniae infection
increased the severity of H1N1 SIV but not that of H1N2 SIV.
Opriessnig et al. (2004) indicated using an experimental study that
M. hyopneumoniae infection potentiates the severity of porcine cir-
covirus type 2 (PCV2)-associated lung and lymphoid lesions,
increases the amount of PCV2-antigen and prolongs its presence,
and increases the incidence of post-weaning multisystemic wasting
syndrome in pigs. Sibila et al. (2012) however, could not demon-
strate an interaction between M. hyopneumoniae and PCV2 infection.
Flesja and Ulvesaeter (1980) reported that the extent of pneu-
monia was associated with the presence of liver lesions due to
migrating Ascaris suum larvae.
Finally, Posa et al. (2013) showed that pigs receiving feed con-
taminated with Fumonisin B elicited more severe lung lesions upon
M. hyopneumoniae challenge infection compared to pigs fed with
non-contaminated feed. Pigs that received feed contaminated with
the mycotoxin deoxynivalenol (DON) did not develop more severe
disease and lesions upon experimental M. hyopneumoniae infection
than pigs fed with non-contaminated feed (Michiels et al., 2016). A
full review of all interactions between different respiratory patho-
gens has been published by Opriessnig, Gimenez-Lirola, and Halbur
(2011).
5 | CLINICAL SIGNS AND LESIONS
Infections with M. hyopneumoniae are clinically characterized by an
intermittent, variable in intensity, dry non-productive cough (Sibila
et al., 2009), which may last from weeks to months. When this type
of coughing affects simultaneously many animals of different ages,
also other pathogens such as SIV or PRRSV may be involved in the
problem (Nathues et al., 2012). Under an endemic scenario, disease
course implies high morbidity but low mortality. When M. hyopneu-
moniae enters into a na€ıve population, the disease may be more sev-
ere, affecting animals of all ages and increasing the morbidity up to
100% (Thacker & Minion, 2012). If other bacterial and/or viral
agents are involved, or in case of poor air quality due to particulate
matter and ammonia (Michiels et al., 2015), clinical signs may be
aggravated including laboured breathing, pyrexia, anorexia, lethargy
and even death (Maes, Verdonck, Deluyker, & de Kruif, 1996). In
uncomplicated cases, a variable proportion of animals might remain
subclinically infected for several weeks (Fano et al., 2005), with no
evidence of coughing or pulmonary lesions at slaughter.
Coughing is the direct consequence of the lung lesions observed
in affected animals, which consist of purple to grey consolidated
areas affecting the apical and middle lobes and, eventually, cranial
part of diaphragmatic lobes (Garcıa-Morante et al., 2016). In case of
secondary bacterial infections, pigs show heavier and firmer lungs
with higher proportion of tissue affected, and grey-to-white mucop-
urulent exudate in the airways. In recovered lesions, whitish firm and
thickened interlobular connective tissue formation (scars) can be
observed (Thacker & Minion, 2012).
Both clinical signs and macroscopic lesions are suggestive, but
not exclusive, of M. hyopneumoniae infection. Other pathogens such
as SIV or P. multocida should be considered within the most proba-
bly differential diagnoses (Sibila et al., 2009). Pasteurella multocida is
considered a secondary pathogen, following infection with M. hyop-
neumoniae or another pathogen. Infections with P. multocida may
cause catarrhal-purulent pneumonia, which is grossly seen as cran-
ioventral pulmonary consolidation (Register, Brockmeier, de Jong, &
Pijoan, 2012). At microscopic level, M. hyopneumoniae produces a
well-differentiated broncho-interstitial pneumonia. At early stages of
infection, perivascular and peribronchiolar lymphoplasmacytic hyper-
plasia, pneumocyte type II hyperplasia and oedema fluid in the alve-
olar spaces with the presence of neutrophils, macrophages and
plasma cells are observed (Blanchard et al., 1992). As disease pro-
gresses, these lesions are aggravated with an evident peribronchial
and perivascular lymphoid follicles (Sibila et al., 2007), with an
increased number of goblet cells and hyperplasia of submucosal
glands (Thacker & Minion, 2012).
Intensity of clinical signs and severity of lesions may depend on
different factors, such as management, environmental conditions and
M. hyopneumoniae strain. Information on the impact of strain vari-
ability may exert on lung lesions severity and clinical signs onset and
duration is still not well defined. Whereas it has been reported that
co-infection with more than one strain resulted in more severe
lesions (Michiels et al., 2017; Villarreal et al., 2009), such potentia-
tion was not observed in others (Charlebois et al., 2014). To date,
the lack of a known virulence marker together with the coexistence
of different strains at individual and farm levels (Nathues, Grosse
Beilage, Kreienbrock, Rosengarten, & Spergser, 2011; Pantoja, Pettit,
Dos Santos, Tubbs, & Pieters, 2016; Vranckx, Maes, Del Pozo
Sacristan, Pasmans, & Haesebrouck, 2012a; Vranckx et al., 2011),
prevent knowing the impact of a particular strain on the severity of
clinical signs and lung lesions.
6 | SOCIO-ECONOMIC IMPACT
Mycoplasma hyopneumoniae is a species-specific pathogen of suids.
Therefore, it is not of zoonotic concern and no impact on public
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health is considered. However, infections with M. hyopneumoniae
cause major economic losses to the pig industry, mainly because of
reduced performance, uneven growth, increased number of days to
reach slaughter weight, treatment and control costs, and increased
mortality in case of complicated infections (Holst et al., 2015).
Unfortunately, few updated information on the economic impact of
EP is available, and existing data have been mostly generated by
assessing the relationship between evaluation of lung lesions at
slaughterhouse with average daily weight gain (ADWG). Whereas a
reduction of 6%–16% in the growth rate in finishing pigs was
reported by some authors (Pointon et al., 1985, Rautiainen, Virtala,
Wallgren, & Saloniemi, 2000), no impact of lung lesions on ADWG
at experimental (Escobar, Van Alstine, Baker, & Johnson, 2002;
Garcıa-Morante et al., 2015) or natural (Scheidt et al., 1990; Straw,
Tuovinen, & Bigras-Poulin, 1989) conditions was detected by other
authors. The economic impact of M. hyopneumoniae subclinical infec-
tion has been inferred only once from the difference in ADWG
(38 g/day) between seropositive and seronegative pigs from 18 dif-
ferent cohorts (Regula et al., 2000). The importance of subclinical
infections should be further studied, especially in eradication pro-
grammes.
7 | DIAGNOSTICS
Clinical signs and lung lesions can lead to a tentative diagnosis, but
laboratory testing is necessary for a conclusive diagnosis. The use of
remote systems for cough recording at the barn level and analysis
appears to be a potential tool for early EP detection, although such
systems have not been validated for M. hyopneumoniae infections in
the field.
Bacterial isolation remains a confirmatory method for pathogen
detection; however, the requirement to use specialized media, the
high cost associated with the technique, the common overgrowth of
other bacteria in the sample and the low sensitivity of the method
make significant detractors for this approach. Nevertheless, recent
work from Cook, Beddow, Manso-Silvan, Maglennon, and Rycroft
(2016) promises to aid controlling bacterial overgrowth with M. hy-
orhinis, and data from Ferrarini et al. (2016) may help with develop-
ment of the highly needed media specifically suited for
M. hyopneumoniae growth. Improving M. hyopneumoniae culture and
isolation methods will help increasing strain collections, which can
be used for research, diagnostics and vaccine development, and eval-
uation of antimicrobial sensitivity testing.
Tissue detection of M. hyopneumoniae can be accomplished with
several techniques, including immunohistochemistry (IHC; Opriessnig
et al., 2004), in situ hybridization (ISH; Boye, Jensen, Ahrens, Hage-
dorn-Olsen, & Friis, 2001) and PCR (Dubosson et al., 2005; Strait
et al., 2008). In situ hybridization and ISH allow for detection of
M. hyopneumoniae in the target tissue; however, this feature can be
considered a limiting factor, as only small tissue sections can be eval-
uated. The application of PCR has allowed for a significant increase
in the detection of M. hyopneumoniae in multiple sample types, and
nowadays, real-time PCR constitutes one of the most common
methods for M. hyopneumoniae detection (Dubosson et al., 2005;
Strait et al., 2008). Real-time PCR is characterized for its high speci-
ficity and sensitivity. Samples collected from the M. hyopneumoniae
target tissue, such as bronchi and bronchioles in the lower respira-
tory tract, exhibit a higher sensitivity compared to samples obtained
from the upper respiratory tract. In vivo sampling by means of tra-
cheo-bronchial (Fablet et al., 2010) or laryngeal (Pieters, Daniels, &
Rovira, 2017) swabs tested by real-time PCR appears to offer a high
sensitivity, at least during the early stages of EP. Oral fluid samples
tested by PCR have shown low sensitivity when compared to other
sample types (Pieters et al., 2017), especially before clinical signs are
evident. Further, Hernandez-Garcia et al. (2017) showed the lack of
consistency of M. hyopneumoniae detection with the use of oral flu-
ids, even after long periods of time post-infection. Ideally, an in vivo
sample obtained from the bronchioles, and of easy collection, is envi-
sioned by swine practitioners.
Circulating antibodies (IgG) can be detected in pigs exposed to
M. hyopneumoniae. Antibodies are developed several weeks after ini-
tial infection (Thacker & Minion, 2012), can be the result of maternal
antibody absorption in piglets (Bandrick, Pieters, Pijoan, & Molitor,
2008) or can be generated after vaccination (Maes et al., 2008).
Antibodies against M. hyopneumoniae can be detected with ELISA
tests regardless of origin, which complicates interpretation. Also, in
the chronic phase of infection, antibodies against M. hyopneumoniae
wane and are no longer detected. Commercial ELISA kits are avail-
able for M. hyopneumoniae antibody detection, and although based
on different antigens and ELISA platforms, they exhibit similar accu-
racy (Erlandson, Evans, Thacker, Wegner, & Thacker, 2005; Pieters
et al., 2017) and are equally unable to differentiate pigs that have
been vaccinated from those that have suffered from the disease.
The use of several serological parameters to forecast lifetime pneu-
monia was assessed under natural and experimental conditions. The
IgG2 OD values at systemic levels showed the best correlation with
M. hyopneumoniae-associated lung lesions severity (Garcıa-Morante
et al., 2017). Further research is warranted to improve ELISAs,
including discrimination between infected and vaccinated pigs, and
providing higher specificity.
8 | PREVENTION AND CONTROL
8.1 | Management and biosecurity
Avoiding the introduction of M. hyopneumoniae into negative farms
is crucial to remain free from the infection. While M. hyopneumo-
niae-specific biosecurity measures have not been developed, the use
of general strategies is recommended to maintain a M. hyopneumo-
niae-free status or to elude the introduction of new bacterial strains
into herds. For example, the use of farm air filtration systems, usually
in place to avoid infections with PRRSV, is becoming popular in sow
farms in North America. However, the specific effect of air filtration
systems on reduction in M. hyopneumoniae infections or the value in
area control programmes has not been evaluated.
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Introduction of M. hyopneumoniae via fomites does not appear to
be a high risk for farms, and regular disinfection and decontamina-
tion systems are thought to be effective against this bacterium. Of
special importance is the fact that M. hyopneumoniae survival outside
of the host is limited, based on the pathogen dependence on the
host environment. Nevertheless, data from Browne et al. (2017) sug-
gest that M. hyopneumoniae can survive outside of host on certain
plastic surfaces and in dust for up to 8 days when temperatures are
low (4°C). This information highlights the need to keep decontamina-
tion systems in place in order to avoid pathogen introduction.
The highest risk for pathogen introduction to swine farms resides
in incoming pigs, and this is especially important for M. hyopneumo-
niae infections. The epidemiological features of this bacterium make
it difficult for early detection and clinical presentation, although test-
ing protocols, generally based on serological testing, are in place and
are widely used to screen unvaccinated incoming pigs for M. hyop-
neumoniae infections. However, clinical outbreaks have been
reported months after the suspected pathogen introduction, when
control is far from being effective. Therefore, the development of
diagnostic protocols aimed at early detection and surveillance are of
paramount importance.
8.2 | Therapeutics
Antimicrobials active against M. hyopneumoniae include tetracyclines,
15- and 16-membered ring macrolides, lincosamides, pleuromutilins,
fluoroquinolones, florfenicol, aminoglycosides and aminocyclitols
(Hannan, Windsor, de Jong, Schmeer, & Stegeman, 1997). M. hyop-
neumoniae is intrinsically resistant to antibiotics which interfere with
the polymerization of cell wall precursors, such as beta-lactam antibi-
otics, and to polymyxins, 14-membered ring macrolides (such as ole-
andomycin and erythromycin), rifampin, trimethoprim and
sulphonamides. Acquired resistance has been documented for tetra-
cyclines, 16-membered ring macrolides (tylosin, tilmicosin), lin-
cosamides (lincomycin) and fluoroquinolones (Le Carrou et al., 2006;
Stakenborg et al., 2005; Tavio, Poveda, Assunc~ao, Ramırez, &
Poveda, 2014; Thongkamkoon et al., 2013; Vicca et al., 2007). The
susceptibility to valnemulin and tiamulin may have decreased in the
period 1997 (Hannan et al., 1997) to 2013 (Tavio et al., 2014;
Thongkamkoon et al., 2013). However, taken together, acquired
antimicrobial resistance does currently not seem to constitute a
major problem for treatment of M. hyopneumoniae infections (Klein
et al., 2017), although the situation may be different for other bacte-
ria complicating these infections. Finally, within a farm, strains with
differences in antibiotic susceptibility may coexist (Thongkamkoon
et al., 2013).
Many different studies have shown the efficacy of various
antimicrobials for the treatment and control of M. hyopneumoniae
infections (reviewed by Del Pozo Sacristan, 2014). For most antimi-
crobials tested, performance improved, and lung lesions as well as
clinical signs decreased. Results of treating field cases of EP may be
disappointing because the disease signs and the shedding of micro-
organisms tend to reappear after cessation of the therapy.
8.3 | Vaccines
Vaccination is widely applied worldwide to control M. hyopneumo-
niae infections. Commercial vaccines mostly consist of inactivated,
adjuvanted whole-cell preparations that are administered intramus-
cularly (Maes et al., 2008). Table 1 gives an overview of different
commercially available M. hyopneumoniae bacterin vaccines.
Recently, an inactivated vaccine based on soluble antigens of
M. hyopneumoniae is also commercially available (USA: Fostera PCV
MH, Zoetis; in Europe: Suvaxyn Circo + MH RTU, Zoetis). It is a
one-shot vaccine combined with PCV2 that can be administered to
piglets from 3 weeks of age onwards. In addition, attenuated vacci-
nes against M. hyopneumoniae have been licensed in China (Feng
et al., 2013) and Mexico. The vaccine in Mexico is a thermosensi-
tive mutant of M. hyopneumoniae (VaxSafe MHYO, Avimex).
Vaccination reduces clinical signs and lung lesions and improves
performance. Also, commercial vaccines reduce the number of
organisms in the respiratory tract (Meyns et al., 2006; Vranckx et al.,
2012b) and decrease the infection level in a herd (Sibila et al., 2007).
However, studies under experimental (Meyns et al., 2006) and field
conditions (Pieters, Fano, Pijoan, & Dee, 2010; Villarreal et al.,
2011b) showed that vaccination conferred only a limited reduction
in the transmission ratio of M. hyopneumoniae.
The exact mechanisms of protection are not yet fully under-
stood. Studies suggest that systemic cell-mediated immune
responses are important for protection (Marchioro et al., 2013).
Vranckx et al. (2012b) reported a lower infiltration of macrophages
in the lung tissue in vaccinated animals upon infection with M. hyop-
neumoniae, indicating that vaccination modulates the immune
response following infection. The importance of local mucosal anti-
bodies remains unclear. The serum M. hyopneumoniae-specific anti-
bodies raised after vaccination are not suited to evaluate protective
immunity (Djordjevic et al., 1997).
Different vaccination strategies have been adopted, depending on
the type of herd, production system and management practices,
infection pattern and preferences of the pig producer. Vaccination of
piglets, applied once or twice, is most commonly used. Single vaccina-
tion at either 7 or 21 days of age was efficacious in a pig herd with
clinical respiratory disease during the second half of the fattening
period (Del Pozo Sacristan et al., 2014). Recent experimental (Arse-
nakis et al., 2016) and field studies (Arsenakis et al., 2017a) showed
that vaccinating piglets 3 days prior to weaning conferred slightly
better results than vaccination at weaning, possibly because of less
interference of weaning stress.
Vaccination confers beneficial effects in most infected herds,
but variable effects are obtained. This may be due to different fac-
tors such as improper vaccine storage conditions and administration,
vaccination compliance, infection level, diversity of M. hyopneumo-
niae strains and co-infections. The influence of maternally derived
antibodies on vaccine responses in piglets is not fully elucidated.
Martelli, Terrini, Guazzetti, and Cavirani (2006) showed that pas-
sively acquired antibodies have little or no effect on either a vac-
cine-induced priming or subsequent anamnestic response.
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Sibila et al. (2008) and Arsenakis, Michiels, Boyen, Haesebrouck,
and Maes (2017b) showed that vaccination of sows at the end of
gestation resulted in a lower number of M. hyopneumoniae colonized
piglets at weaning. Breeding gilt vaccination is recommended in
endemically infected herds to avoid destabilization of the breeding
stock immunity (Bargen, 2004).
Constant effort is being directed towards the investigation of
new vaccines that may offer a better protection against M. hyop-
neumoniae infections. In one study (Villarreal et al., 2009), infection
with a low virulent M. hyopneumoniae isolate did not protect pig-
lets against infection with a highly virulent M. hyopneumoniae iso-
late 1 month apart, suggesting that low virulent strains might not
be suitable as such to be used as vaccines. Further research
however is needed. Several studies have evaluated recombinant
proteins of M. hyopneumoniae in various forms of administration
and formulations. Table 2 summarizes the antigens, adjuvants, vec-
tors and routes of immunization used in the studies on experi-
mental M. hyopneumoniae vaccines. Most of the recombinant
proteins were evaluated only in mice, and only a few of them
were tested in challenge experiments in pigs. Some of the vacci-
nes conferred protection and may represent a promising tool for
controlling M. hyopneumoniae infections in pigs. However, valida-
tion in pigs under experimental and practical circumstances is
needed.
9 | ELIMINATION
Successful elimination of M. hyopneumoniae from swine herds has
been reported over decades (reviewed by Holst et al., 2015), and
several protocols have been developed. Besides depopulation and
repopulation, initial efforts for disease elimination were based on the
Swiss method (Zimmermann, Odermatt, & Tschudi, 1989). This
method includes partial depopulation (i.e., culling of all animals
younger than 10 months of age) and whole herd medication, along
with a 2-week farrowing pause towards the end of the protocol.
While this method has proven highly successful, its application in
large herds is difficult. Thus, other protocols such as herd closure
and medication, and whole herd medication, keeping young animals
at the farms and piglet production undisturbed, have been developed
(Holst et al., 2015). The herd closure and medication strategy allows
for the introduction of replacement gilts at the beginning of the pro-
cess, relies on early exposure of the incoming females, and calls for
no further introduction of susceptible animals for a period of at least
240 days, or when pathogen persistence has no longer been
observed after initial infection (Pieters et al., 2009). In addition, quar-
terly mass vaccination is included as part of herd closure for disease
elimination. On the other hand, the whole herd medication protocol
is usually applied after clinical outbreaks of the disease and does not
require the culling of animals or pause in farrowing. However, the
TABLE 1 Most commonly used commercially available M. hyopneumoniae bacterin vaccines (2017) — Bacterin vaccines available in only one
or a few countries are not included the table
Vaccine Antigen/strain Adjuvant
Route of
administration
Age of
administration
(days)
Boost
needed after
. . .weeks
Hyogen (Ceva) Ceva strain
BA 2940-99
Imuvant (W/O J5 LPS) IM ≥21 —
HYORESP (Merial) NIa Aluminium hydroxide IM ≥5 3–4
INGELVAC MYCOFLEX (Boehringer
Ingelheim)
J strain isolate
B-3745
Impran (water-in-oil adjuvant
emulsion)
IM ≥21 —
M+Pac (Intervet Int.)b NIa Mineral oil and Aluminium hydroxide IM ≥7 3–4
MYPRAVAC SUIS (Hipra Lab) J strain Levamisole and carbomer IM ≥7–10 3
PORCILIS M. HYO (Intervet) Strain 11 dl-a-tocopherol acetate IM ≥7 3
Porcilis PCV M. HYO (MSD-Intervet Int)c J Strain Mineral oil and Aluminium hydroxide IM ≥21 —
Porcilis MHYO ID Once (MSD-Intervet
Int.)
Strain 11 Paraffin oil and dl-a-tocoferylacetaat ID ≥14 —
STELLAMUNE MYCOPLASMA (Eli Lilly) NL 1042 Mineral oil and lecithin IM ≥3 2–4
STELLAMUNE ONE (Eli Lilly) NL 1042 Amphigen Base, and Drakeol 5
(mineral oil)
IM ≥3 —
SUVAXYN M.HYOd (Zoetis) P-5722-3 Carbopol IM ≥7 2
SUVAXYN MH-ONEe (Zoetis) P-5722-3 Carbopol and squalane IM ≥7 —
SUVAXYN M.HYO—PARASUISf (Zoetis) P-5722-3 Carbopol and squalane IM ≥7 2
aNo information available.
bVaccination scheme when 1 ml is used for each administration. No boost vaccination needed if a 2 ml dose is used the first time.
cCombination vaccine with Porcine Circovirus type 2.
dNamed Suvaxyn RespiFend MH in USA.
eSame name is used in the USA, but Amphigen is used as adjuvant in the USA, and vaccine can be administered from day one of age onwards.
fCombination vaccine with Haemophilus parasuis—named Suvaxyn RespiFend MH HPS in USA.
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reported success of disease elimination is lower for this protocol
compared to herd closure (Holst et al., 2015).
Although elimination of M. hyopneumoniae is becoming increas-
ingly common in the USA, several aspects of the protocols and the
potential success could be questioned. For example, concerns exist on
the likelihood to eliminate M. hyopneumoniae in high
pig-dense areas due to potential lateral infection of the herd, although
this does not seem to occur frequently. Scientific information on lat-
eral transmission of M. hyopneumoniae infections is largely missing,
and previous evidence of pathogen airborne transmission can make a
difficult case otherwise (Goodwin, 1985; Otake et al., 2010). Also,
refinement of the elimination protocols is necessary for practicality
TABLE 2 Overview of experimental vaccines against M. hyopneumoniae
Antigen Vaccine type Vector/adjuvant Species Route
Challenge
infection References
P97 Recombinant
Subunit
Complete Freund’s
adjuvant
Pig IM** Yes King, Faulds, Rosey, and
Yancey (1997)
NrdF (R2) Recombinant
Vector
Salmonella Typhimurium
aroA SL3261
Mice Oral No Fagan, Djordjevic, Chin, Eamens, and
Walker (1997)
P97 (R1) Recombinant
Vector
Pseudomonas aeroginosa
exotoxin A
Mice and
pig
SC*** and IM No Chen, Liao, Mao, and Weng (2001)
NrdF (R2) Recombinant
Vector
Salmonella Typhimurium
aroA SL3261
Pig Oral Yes Fagan, Walker, Chin, Eamens, and
Djordjevic (2001)
Strain PRIT-5 Inactivated
whole cell
Spray-dried microspheres Pig Oral Yes Lin, Weng, Liao, Yeh, and Pan (2003)
P42 DNA pcDNA3 Mice IM No Chen et al. (2003)
P97 (R1R2) Recombinant
Vector
Erysipelothrix
rhusiopathiae YS-1
Mice and
pig
SC and IN**** No Shimoji, Oishi, Muneta, Nosaka, and
Mori (2003)
P97 (R1) Recombinant
Vector
Salmonella Typhimurium
aroA CS332
Mice Oral No Chen, Fry, Forbes-Faulkner, Daggard,
and Mukkur (2006a)
NrdF (R2) Recombinant
Vector
Salmonella Typhimurium
aroA CS332
Mice Oral No Chen, Fry, Forbes-Faulkner, Daggard,
and Mukkur (2006b)
P97 (R1) Recombinant
Subunit
LTB Mice IM and IN No Conceic~ao, Moreira, and
Dellagostin (2006)
P97 (R1) Recombinant
Vector
Adenovirus Mice IM and IN No Okamba et al. (2007)
P97 (R1R2) Recombinant
Vector
Erysipelothrix rhusiopathiae
Koganei
Pig Oral Yes Ogawa et al. (2009)
P97 (R1) Recombinant
Vector
Adenovirus Pig IN Yes Okamba et al. (2010)
P36 Recombinant
Vector
Actinobacillus
pleuropneumoniae SLW36
Mice IM No Zou et al. (2011)
34* Recombinant
Subunit
Aluminium Mice IM No Simionatto et al. (2012)
P37, P42,
P46, P95
Recombinant
Subunit and DNA
Aluminium and pcDNA3 Mice IM No Galli et al. (2012)
P97 (R1, R2) Recombinant
chimeric Subunit
Heat-labile enterotoxin
Escherichia coli (LTB) and
Montanide IMS
Mice IM No Barate, Cho, Truong, and
Hahn (2014)
P46, HSP70,
MnuA
Recombinant
Subunit and DNA
Complete Freund’s
adjuvant
Mice Intraperitoneal No Virginio et al. (2014)
P97, P42,
NrdF
Recombinant
chimeric Subunit
Heat-labile enterotoxin
E. coli (LTB)
Pig IM and IN No Marchioro et al. (2014)
HSP70 Recombinant
Subunit
Mesoporous silica
nanoparticles SBa-15
and SBa-16, Aluminium
Mice Intraperitoneal No Virginio et al. (2017)
* 34 previously uncharacterized recombinant proteins of M. hyopneumoniae were evaluated in this study.
** Intramuscularly
*** Subcutaneously
**** Intranasal
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and application in combination with other disease elimination pro-
grammes. Nevertheless, elimination of M. hyopneumoniae from com-
mercial herds, whether alone or in combination with the elimination of
other pathogens, appears to be justified from the ethical and economi-
cal points of view (Yeske, 2016).
10 | CONCLUSION
Mycoplasma hyopneumoniae is a very important pathogen that causes
major losses to the pig industry. Research has focused on the epi-
demiology and transmission in different production systems, partly
elucidated the very complex interaction of the pathogen with the
respiratory tract, and has developed and tested many commercial
and experimental vaccines. However, important knowledge gaps
remain, and therefore, further research is needed to achieve a better
control and possible elimination of the pathogen. The focus should
be on better understanding of the virulence mechanisms and the
interaction of the pathogen with the host and with other pathogens,
and the development of vaccines that confer better protection and
can be administered easily. Finally, research on how to successfully
eliminate the pathogen from pig herds should also be stimulated.
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